XTL Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012 - 2003
Selling, General & Admin	0.85	1	0.91	0.81	0.76	1.2	1.27	1.42	1.74	1.33	Upgrade
Research & Development	0.03	0.03	0.04	0.04	0.04	0.04	0.44	0.58	0.28	0.08	Upgrade
Other Operating Expenses	0	0	0	0	0	0	0.85	1.61	0	-1.06	Upgrade
Operating Expenses	0.88	1.03	0.95	0.84	0.79	1.25	2.56	3.61	2.02	0.35	Upgrade
Operating Income	-0.88	-1.03	-0.95	-0.84	-0.79	-1.25	-2.56	-3.61	-2.02	-0.35	Upgrade
Interest Expense / Income	0	0	0	0	0	0	0	0	0.11	0.01	Upgrade
Other Expense / Income	0.47	-1.47	2.01	-0.08	-4.42	-0.47	-0.02	0.7	0.4	2.12	Upgrade
Pretax Income	-1.35	0.44	-2.95	-0.76	3.63	-0.78	-2.55	-4.31	-2.53	-2.48	Upgrade
Net Income	-1.35	0.44	-2.95	-0.76	3.63	-0.78	-2.55	-4.31	-2.53	-2.48	Upgrade
Shares Outstanding (Basic)	545	532	514	514	514	470	274	264	231	45	Upgrade
Shares Outstanding (Diluted)	545	616	514	514	514	470	274	264	231	45	Upgrade
Shares Change	-11.48%	19.71%	-	-	9.36%	71.58%	3.91%	14.06%	417.04%	9.59%	Upgrade
EPS (Basic)	-0.20	0.10	-0.60	-0.10	0.70	-0.20	-0.90	-1.70	-1.10	-5.50	Upgrade
EPS (Diluted)	-0.20	-	-0.60	-0.10	0.70	-0.20	-0.90	-1.70	-1.10	-5.50	Upgrade
Free Cash Flow	-0.9	-1.05	-0.85	-0.91	-0.82	-1.12	-1.73	-1.86	-2.48	-2.58	Upgrade
Free Cash Flow Per Share	-0.17	-0.20	-0.17	-0.18	-0.16	-0.24	-0.63	-0.71	-1.07	-5.78	Upgrade
EBITDA	-1.35	0.44	-2.95	-0.76	3.63	-0.78	-2.55	-4.31	-2.42	-2.47	Upgrade
EBIT	-1.35	0.44	-2.95	-0.76	3.63	-0.78	-2.55	-4.31	-2.42	-2.47	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).